These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1286155)

  • 1. Drugs active against growth factor and oncogene phosphatidylinositol signalling pathways.
    Powis G
    Semin Cancer Biol; 1992 Dec; 3(6):343-50. PubMed ID: 1286155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth factor and oncogene signalling pathways as targets for rational anticancer drug development.
    Powis G; Kozikowski A
    Clin Biochem; 1991 Oct; 24(5):385-97. PubMed ID: 1760877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances with phospholipid signalling as a target for anticancer drug development.
    Powis G; Berggren M; Gallegos A; Frew T; Hill S; Kozikowski A; Bonjouklian R; Zalkow L; Abraham R; Ashendel C
    Acta Biochim Pol; 1995; 42(4):395-403. PubMed ID: 8852330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth factors, oncogenes and inositol lipids.
    Berridge MJ
    Cancer Surv; 1986; 5(2):413-30. PubMed ID: 3779662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of phosphatidylinositol signalling as antiproliferative agents.
    Powis G; Phil D
    Cancer Metastasis Rev; 1994 Mar; 13(1):91-103. PubMed ID: 8143348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor-mediated signalling pathways acting through hydrolysis of membrane phospholipids in cardiomyocytes.
    Lamers JM; De Jonge HW; Panagia V; Van Heugten HA
    Cardioscience; 1993 Sep; 4(3):121-31. PubMed ID: 8400019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues.
    Berggren MI; Gallegos A; Dressler LA; Modest EJ; Powis G
    Cancer Res; 1993 Sep; 53(18):4297-302. PubMed ID: 8395981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium and the endothelin-1 and alpha 1-adrenergic stimulated phosphatidylinositol cycle in cultured rat cardiomyocytes.
    van Heugten HA; de Jonge HW; Bezstarosti K; Lamers JM
    J Mol Cell Cardiol; 1994 Aug; 26(8):1081-93. PubMed ID: 7528283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
    Comoglio PM
    EXS; 1993; 65():131-65. PubMed ID: 8380735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues.
    Seewald MJ; Olsen RA; Sehgal I; Melder DC; Modest EJ; Powis G
    Cancer Res; 1990 Aug; 50(15):4458-63. PubMed ID: 2369723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effect of hepatocyte growth factor against FaO hepatocellular carcinoma cells may be associated with changes of intracellular signalling pathways mediated by protein kinase C.
    Shiota G; Kawasaki H; Nakamura T; Schmidt EV
    Res Commun Mol Pathol Pharmacol; 1994 Sep; 85(3):271-8. PubMed ID: 7827802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inositol phospholipid-dependent cellular signalling: opportunities for drug discovery.
    Young RC; Downes CP
    Drug Des Deliv; 1990 May; 6(1):1-13. PubMed ID: 1964051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signalling pathways as targets for anticancer drug development.
    Powis G
    Pharmacol Ther; 1994; 62(1-2):57-95. PubMed ID: 7991648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscarinic-receptor-mediated inhibition of insulin-like growth factor-1 receptor-stimulated phosphoinositide 3-kinase signalling in 1321N1 astrocytoma cells.
    Batty IH; Fleming IN; Downes CP
    Biochem J; 2004 May; 379(Pt 3):641-51. PubMed ID: 14769130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple defects in negative regulation of the PKB/Akt pathway sensitise human cancer cells to the antiproliferative effect of non-steroidal anti-inflammatory drugs.
    Lincová E; Hampl A; Pernicová Z; Starsíchová A; Krcmár P; Machala M; Kozubík A; Soucek K
    Biochem Pharmacol; 2009 Sep; 78(6):561-72. PubMed ID: 19433066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ionic signal transduction in growth factor action.
    De Laat SW; Moolenaar WH; Defize LH; Boonstra J; van der Saag PT
    Biochem Soc Symp; 1985; 50():205-20. PubMed ID: 3019351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents.
    Leger DY; Liagre B; Beneytout JL
    Apoptosis; 2006 Oct; 11(10):1747-60. PubMed ID: 16927021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear lipid signalling.
    Irvine RF
    Nat Rev Mol Cell Biol; 2003 May; 4(5):349-60. PubMed ID: 12728269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.